Risk of Second Primary Malignancy Associated with Cumulative Doses of Radioactive Iodine in Patients with Differentiated Thyroid Cancer

Abstract

Clinical ThyroidologyVol. 35, No. 4 Thyroid CancerRisk of Second Primary Malignancy Associated with Cumulative Doses of Radioactive Iodine in Patients with Differentiated Thyroid CancerDavid Toro-Tobon and Omar EI KawkgiDavid Toro-Tobon Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, U.S.A.Search for more papers by this author and Omar EI Kawkgi Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, U.S.A. Department of Endocrinology, Mayo Clinic Health System, Eau Claire, Wisconsin, U.S.A.Search for more papers by this authorPublished Online:11 Apr 2023https://doi.org/10.1089/ct.2023;35.154-156AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 4Apr 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:David Toro-Tobon and Omar EI Kawkgi.Risk of Second Primary Malignancy Associated with Cumulative Doses of Radioactive Iodine in Patients with Differentiated Thyroid Cancer.Clinical Thyroidology.Apr 2023.154-156.http://doi.org/10.1089/ct.2023;35.154-156Published in Volume: 35 Issue 4: April 11, 2023PDF download